

Pennsylvania Department of Environmental Protection (PADEP)

PA PFAS MCL Rule – FAQ

The following information and responses to hypothetical scenarios are provided for informational purposes only. To ensure compliance, please refer to the Pennsylvania's Safe Drinking Water regulations at 25 Pa. Code Chapter 109.

Contents

FAQs for Consumers

General Questions.....	2
Actions Consumers Can Take.....	7
Compliance Monitoring Results	9

FAQs for Water System Operators

Training	11
Monitoring Requirements – General.....	11
Monitoring requirements for consecutives and interconnections	13
Sampling, labs, and analytical methods.....	156
Compliance	178
UCMR 5	191
Cost Estimates.....	225
Bottled, Vended, Retail, and Bulk (BVRB) Water Systems	24
Treatment and Permitting	24
Consumer Confidence Reports (CCR)	25

FAQs for Consumers

General Questions


Q1: What are “PFAS”?

A: Per- and polyfluoroalkyl substances (PFAS) are a large class of human-made synthetic chemicals that were created in the 1930s and 1940s for use in many industrial and manufacturing applications. It is estimated that the PFAS family includes more than 6,000 chemical compounds. PFAS have been widely used for their unique properties that make products repel water, grease and stains, reduce friction and resist heat.

PFAS are found in industrial and consumer products such as clothing, carpeting, upholstery, food packaging, non-stick cookware, fire-fighting foams, personal care products, paints, adhesives, metal plating and wire manufacturing and many other uses. Unfortunately, many manufacturers do not provide information about which products contain PFAS.

Q2: Why are PFAS a concern?

A: Due to their chemical structure, PFAS do not readily break down when exposed to air, water, or sunlight, so they persist in the environment and are sometimes referred to as “forever chemicals”. PFAS chemicals easily dissolve in water and can build up (bioaccumulate) in people, animals and the environment over time. Decades of widespread use of products containing PFAS has resulted in elevated levels of environmental pollution and exposure in some areas our planet, including some parts of Pennsylvania. PFAS have been found in water, air and soil across the nation and around the globe. Because of this, PFAS can end up in the water sources that communities rely on for drinking water.



Scientific studies show links between certain levels of PFAS exposure and harmful chronic health effects in humans and animals. PFAS are potentially linked to a number of adverse health effects, including high cholesterol, developmental effects including low birth weight, liver toxicity, decreased immune response, thyroid disease, kidney disease, ulcerative colitis and certain cancers, including testicular cancer and kidney cancer. Additional information on the health effects of PFAS exposure is available in the Pennsylvania Department of Health (PADOH)'s [PFAS Fact Sheet](#).

Q3: How can I be exposed to PFAS?

A: An individual’s exposure to PFAS can vary due to a number of factors. The primary means of distribution of PFAS throughout the environment has been through the air, water, biosolids, food, landfill leachate and fire-fighting activities. Certain PFAS have been detected in water and soil near waste sites; areas where fire-extinguishing foam has been used and around manufacturing or chemical production facilities that produce or use PFAS. PFAS can also be found in certain foods, food packaging, household products, personal care products, dust, and biosolids.

Current research shows that people can be exposed to PFAS by working in occupations such as firefighting or chemical manufacturing and processing, eating certain foods such as fish that may contain PFAS, swallowing contaminated soil or dust, breathing air containing PFAS, or using products made with PFAS or that are packaged in materials containing PFAS. When a person’s drinking water is contaminated with PFAS, it can be a significant portion of their total PFAS exposure. However, due to the prevalence of PFAS in consumer products, it is likely that most people have been exposed to these substances at some point.

Q4: What motivated the PA DEP efforts to regulate PFAS?

A: The Pennsylvania Department of Environmental Protection (PADEP) first became aware of PFAS in drinking water in 2013, when the United States Environmental Protection Agency (EPA) released its Third Unregulated Contaminant Monitoring Rule (UCMR 3). UCMR 3 required monitoring for 30 unregulated contaminants in drinking water, including six PFAS. In 2018, then-Governor Tom Wolf issued an executive order establishing the PFAS Action Team. The Governor tasked this multi-agency team with developing a comprehensive response to identify and eliminate sources of PFAS contamination, ensure drinking water is safe, and manage environmental contamination from PFAS. Because PFAS have been used for several decades in the manufacturing of a range of products (including certain fabrics, carpets, cookware and food packaging) and are present in certain types of fire-fighting foams, PADEP has documented PFAS contamination at a number of sites throughout the state.

As part of Pennsylvania’s PFAS Action Team, DEP took a major step to protect Pennsylvanians from the adverse health effects associated with two PFAS by establishing limits for PFOA (perfluorooctanoic acid) and PFOS (perfluorooctane sulfonic acid) in drinking water provided by public water systems in Pennsylvania. PADEP’s PFAS Maximum Contaminant Level (MCL) Rule was published in the *Pennsylvania Bulletin* on January 14, 2023 at [53 Pa.B. 333](#), establishing enforceable standards for PFOA and PFOS in drinking water provided by public water systems in Pennsylvania. A summary of Pennsylvania’s PFAS MCL Rule is in the PADEP Bureau of Safe Drinking Water’s [January 2023 Drinking Water News newsletter](#).

By finalizing a Pennsylvania-specific PFAS MCL rule ahead of EPA’s PFAS National Primary Drinking Water Regulation, PADEP provided Pennsylvanians with several years earlier protection from the adverse health effects associated with exposure to these chemicals and also gave public water systems in Pennsylvania several years to begin earlier sampling for these chemicals and evaluating options to address elevated levels, where found.

Q5: Should Pennsylvania residents be concerned about the presence of these chemicals in their water?

A: With the finalization of PADEP’s PFAS MCL Rule, PFOA and PFOS are now regulated in public drinking water in Pennsylvania. The benefits associated with reductions of PFOA and PFOS in drinking water arise from a reduction in adverse chronic human health effects. Exposure to PFOA is associated with adverse developmental effects (including neurobehavioral and skeletal effects) and exposure to PFOS is associated with adverse immune system impacts (including immune suppression).

The PADEP Bureau of Safe Drinking Water’s PFAS MCL Rule was published in the *Pennsylvania Bulletin* on January 14, 2023 at [53 Pa.B. 333](#) and is summarized in the PADEP [January 2023 Drinking Water News newsletter](#). The rule also establishes the provisions necessary for public water systems to comply with the MCLs, including requirements for monitoring and reporting, public notification, consumer confidence reports, best available treatment technologies and analytical requirements.

DEP’s finalized drinking water PFAS MCL Rule is a major step towards protecting Pennsylvanians from the adverse chronic health effects associated with certain PFAS. In addition to drinking water, PADEP has conducted [PFAS sampling in surface waters](#) in Pennsylvania and has documented PFAS contamination in [fish tissue](#).


Q6: What are the PA DEP Maximum Contaminate Levels for PFOS and PFOA?

A: The Maximum Contaminant Level (MCL) is the maximum or highest level of a contaminant that is allowed in drinking water delivered to customers. Pennsylvania’s PFOS and PFOA MCLs are measured in units of parts per trillion. One part per trillion (ppt) is equivalent to a single drop of water in 20 Olympic-sized swimming pools.

1 part per trillion (ppt)

IS EQUIVALENT TO A SINGLE DROP OF WATER IN

20 olympic-sized swimming pools



PADEP set the PFOS Maximum Contaminate Level (MCL) enforceable standard at 18 ppt and the PFOA MCL enforceable standard at 14 ppt.

PA DEP Maximum Containment Level for PFOS and PFOA

Contaminant Name	MCL in ppt
Perfluorooctane sulfonate (PFOS)	18 ppt
Perfluorooctanoic acid (PFOA)	14 ppt

A summary of Pennsylvania’s drinking water PFAS MCL Rule is in the PADEP Bureau of Safe Drinking Water’s [January 2023 Drinking Water News newsletter](#).

Q7: What are the benefits of Pennsylvania having state level PFAS regulations? Only a few states have them; how will Pennsylvania residents benefit from being one of those states?

A: Pennsylvania’s PFAS MCL Rule set MCLs for contaminants in drinking water that were, until very recently, unregulated at the federal level. With this rule, the Commonwealth moved ahead of EPA in addressing PFOA and PFOS in drinking water and joined a small group of states that set regulatory limits for select PFAS in drinking water ahead of EPA. Seven other states set MCLs or other regulatory limits for one or more PFAS ahead of EPA—Massachusetts, Michigan, New Hampshire, New Jersey, New York, Vermont and Washington. Proactively addressing PFOA and PFOS contamination in drinking water can reduce the incidence of illness and reduce health care costs. By finalizing a Pennsylvania-specific PFAS MCL rule ahead of EPA’s PFAS National Primary Drinking Water Regulation, PADEP provided Pennsylvanians with several years earlier protection from the adverse health effects associated with exposure to these chemicals and also gave public

water systems in Pennsylvania several years to begin earlier sampling for these chemicals and evaluating options to address elevated levels, where found.

Q8: What is the difference between a Health Advisory Level (HAL), Maximum Containment Level Goal (MCLG) and Maximum Contaminant Level (MCL)?

A: A Health Advisory Level (HAL) is not an enforceable standard, but HALs provide information on contaminants that can cause human health effects and are known or anticipated to occur in drinking water. A lifetime HAL is the concentration of a chemical in drinking water that is not expected to cause any adverse noncarcinogenic effects over a lifetime of exposure. A lifetime HAL is based on exposure of a 70-kilogram (150 pound) adult consuming 2 liters (½ gallon) of water per day. EPA's lifetime health advisories also take into account other potential sources of exposure beyond drinking water (for example, food, air, consumer products, etc.), which provides an additional layer of protection.

Maximum Contaminant Level Goal (MCLG) is a non-enforceable health benchmark goal which is set at a level at which no known or anticipated adverse effects on the health of persons is expected to occur and which allows an adequate margin of safety. MCLGs are non-enforceable health goals, developed solely based on health effects, including those for sensitive populations like pregnant people, developing babies and infants, children, elderly, and immune-compromised individuals. MCLGs do not take into consideration other factors, such as technical limitations, treatability, and cost. Therefore, MCLGs are sometimes set at levels that water systems cannot meet because of current technological limitations.

A Maximum Contaminant Level (MCL) is an enforceable standard that is the maximum or highest level of a contaminant that is allowed in drinking water delivered to customers by public water systems. The MCL are set as close to the MCLG as feasible using the best available analytical and treatment technologies and taking cost into consideration. The federal Safe Drinking Water Act requires EPA to prepare a health risk reduction and cost analysis in support of any drinking water standard. The EPA must analyze all benefits that are likely to occur as the result of compliance with the proposed standard. EPA must also analyze increased costs that will result from the proposed drinking water standard. In addition, EPA must consider incremental costs and benefits associated with proposed alternative MCL values. Where the benefits of a new MCL do not justify the costs, EPA may adjust the MCL to a level that maximizes health risk reduction benefits at a cost that is justified by the benefits.

Q9: How did PADEP arrive at the MCLs to regulate PFOA and PFOS in drinking water?

A: In December 2019, PADEP's Bureau of Safe Drinking Water executed a toxicology services contract with Drexel University to: review other state and federal agency work on PFAS MCLs; independently review the data, science, and studies; and develop recommended MCLGs for select PFAS. The Drexel PFAS Advisory Group (DPAG) contracted by PADEP was comprised of a group of medical toxicologists and experts in the fields of environmental engineering and public health. The DPAG reviewed pertinent literature and work across the country and independently developed recommended MCLGs based on non-cancer endpoints. The deliverables to PADEP from DPAG's work include three reports that are available on the PADEP Bureau of Safe Drinking Water's [PFAS MCL Rule webpage](#).

DPAG identified the target population for PFOA and PFOS as infant exposure via breastmilk for one year, from a mother chronically exposed via water, followed by lifetime exposure via drinking water. The MCLG recommendations were the basis for development of the MCLs. PADEP set the MCLs at 14 ppt for PFOA and 18 ppt for PFOS based on the health effects and MCLGs, occurrence data, technical feasibility, treatability, and costs and benefits analysis.

The scientific research, data and studies on PFAS are continually evolving, and there is inherent variability and uncertainty in the field of toxicology. There are numerous variables, including the selection of health-based endpoints and critical studies, different models for determining reference doses, assumptions in applying animal studies, estimating relative source contribution and other uncertainty factors that can lead to wide variability in calculated outcomes. However, despite these variables, PADEP's PFAS MCL Rule is scientifically derived and provides improved public health protection to Pennsylvanians through a reduction in chronic health effects by reducing concentrations of PFOA and PFOS in drinking water.

PADEP followed a rigorous process when setting the drinking water MCLs in Pennsylvania's PFAS MCL Rule. An MCL rulemaking must be based on available data, studies and science, and must consider all factors as required by the federal Safe Drinking Water Act and the Commonwealth's Regulatory Review Act. Among other things, PADEP was required to consider the following in setting MCLs for PFOA and PFOS:

- Health effects,
- Occurrence data,
- Technical limitations such as available analytical methods and detection and reporting limits,
- Treatability of the contaminant and available treatment technologies, and
- Costs and benefits.

In addition to Pennsylvania-specific requirements, PADEP was also required to consult the federal Safe Drinking Water Act and its implementing regulations. EPA explains how the agency sets standards on their [How EPA Regulates Drinking Water Contaminants webpage](#).

In establishing the MCLs in Pennsylvania's PFAS MCL Rule, PADEP was informed by EPA's procedure to establish an MCL. It is important to understand EPA's process of setting an MCL because similar criteria are required of PADEP under the Commonwealth's RRA. In addition, to retain primacy for implementing the federal Safe Drinking Water Act in Pennsylvania, PADEP's standard setting process must have been at least as stringent as the federal process. PADEP set the MCLs at 14 ppt (PFOA) and 18 ppt (PFOS) because these levels strike the appropriate balance of the relevant factors noted above. The EPA HALs for PFOA and PFOS that were current at the time PADEP developed Pennsylvania's PFAS MCL Rule were not enforceable standards and were not technically feasible because the then-current analytical methods were not capable of detecting levels that low.

Q10: Are public water systems (PWSs) in Pennsylvania testing drinking water for PFAS?

A: In Pennsylvania, beginning January 1, 2024, community water systems (CWS) and nontransient noncommunity water systems (NTNCWS) serving more than 350 people and bottled, vended, retail, and bulk systems (BVRBs) were required to start sampling for PFAS for four consecutive calendar quarters at each entry point (EP) to PWSs' distribution systems. (Definitions of CWS, NTNCWS, and BVRB can be found in PADEP's Safe Drinking Water regulations at [25 Pa. Code § 109.1](#); these regulatory definitions are also provided in the answer to FAQ #28 below.)

Beginning January 1, 2025, CWS and NTNCWS serving less than 350 people are required to sample for PFAS for 4 four consecutive calendar quarters at each entry point (EP) to the distribution system.

Repeat monitoring is quarterly, annual or triennial based on whether analytical results are detected and at what level.

Q11: What if there is PFOS and/or PFOA over PADEP's MCLs?

A: All PWSs are required to notify PADEP within one hour of being notified by their certified laboratory if any single drinking water sample result exceeds an MCL value or if the system is determined to be in

violation of an MCL. An initial consultation with PADEP typically occurs during this notification regarding next steps.

When a PWS is in violation of an MCL, PADEP issues a Notice of Violation (NOV), which contains requested actions and associated timeframes, including a request for the PWS to consult with PADEP to determine appropriate corrective actions. In addition to the requirement to issue public notification to inform their consumers of the MCL violation, corrective actions may include additional or increased monitoring, installation of treatment, using alternative sources, blending sources, taking a source offline, or interconnections with another water system. PWSs are responsible for taking all corrective actions necessary to protect public health and reduce risks from PFAS exposure.

CWSs are required to include monitoring results of all detected contaminants in their annual Consumer Confidence Report (CCR) in order to inform their customers.

Q12: What is PADEP’s response to an exceedance or violation of the PFOS or PFOA MCL?

A: The exact corrective actions in response to an MCL exceedance or violation are not codified in regulation because they are case-specific and may vary based on each individual situation and system specific considerations, including the level detected, any known or suspected source of contamination, other water sources available, and treatment processes already in place. Sufficient quarterly monitoring data may be necessary to evaluate whether there are seasonal variations in contaminant levels in order to identify the most appropriate corrective actions.

Actions Consumers Can Take

Q13: How do I know if there are PFAS in my drinking water?

A: If you are concerned about PFAS in your drinking water, EPA and PADEP recommend you contact your local water utility to learn more about your drinking water and to see whether they have monitoring data for PFAS or can provide any specific recommendations for your community.

Q14: How will I know if my drinking water contains PFAS over an MCL?

A: If your water system experiences an MCL violation for PFOA or PFOS, they are required to notify you of the violation within 30 days using a Public Notification (PN) form and certify they have done so to PADEP.

Q15: What is a Public Notification (PN) form and what information does it contain?

A: The PN form includes information on the date samples were collected, the levels detected, whether you need to take any action and what is being done. Because PFAS are linked to chronic health effects, the PN form states that the MCL violation is not an immediate risk, but that chronic exposure to PFOS and PFOA over certain levels may result in adverse health effects. If you have specific health concerns, consult your doctor.

Q16: Can I test for PFAS in drinking water myself?

A: If you choose to test your water yourself, it is important to use a state-certified laboratory using EPA-approved testing methods. You can search PADEP-accredited environmental labs on PADEP’s [Laboratory Accreditation Program webpage](#); scroll down to the “Search Environmental Laboratories” section for instructions and access to the database of accredited labs.

Q17: Where can I find information on the drinking water quality my public water system (PWS) is providing?

A: The best place to find information pertaining to the drinking water quality, source water quality, actions taken to restore safe drinking water and contact information for your public water system would be your PWS's Consumer Confidence Report (CCR). Your PWS's CCR must be sent out by July 1st each year and is available upon request from your water supplier or may be found using [EPA's CCR search tool](#).

Q18: What if I have a private well?

A: Under the Pennsylvania Safe Drinking Water Act, PADEP does not have the authority to regulate private water sources or enforce standards for public water systems on privately owned wells. However, PADEP maintains a [Private Water Wells webpage](#) to help educate private well owners on water testing, contaminants, well construction, treatment and other information.

If you choose to test your water yourself, it is important to use a state-certified laboratory using EPA-approved testing methods. You can search PADEP-accredited environmental labs on DEP's [Laboratory Accreditation Program webpage](#); scroll down to the "Search Environmental Laboratories" section for instructions and access to the database of accredited labs.

Private well owners can also learn more about private drinking water wells and PFAS on EPA's [Private Drinking Water Wells webpage](#) and [Meaningful and Achievable Steps You Can Take to Reduce Your Risk webpage](#).

More information and private well testing can be found at Penn State Extension's [Testing Your Drinking Water webpage](#).

Q19: Can I use my water if PFOA and/or PFOS are detected in it?

A: You do not need to use an alternate water supply for drinking, cooking, bathing or brushing teeth. PFAS are chronic contaminants, so adverse health effects are generally associated with long-term exposure. However, if you have specific health concerns, you should consult your doctor.

Additional information on the health effects of PFAS exposure is available in the Pennsylvania Department of Health (PADOH)'s [PFAS Fact Sheet](#). For example, according to PADOH, water may be used to wash hands, bathe and wash dishes. Studies have shown that only a very small amount of PFAS may be absorbed through the skin, which is referred to as dermal exposure.

If you are concerned about the level of PFAS in your drinking water, you should consider installing in home water treatment (such as filters) that are certified to lower the levels of PFAS in your water. For more information, see EPA's fact sheet, [Reducing PFAS in Your Drinking Water with a Home Filter](#).

Q20: What are some of the highlights of Pennsylvania's PFAS MCL Rule that I should know about?

A: Pennsylvania's PFOA and PFOS MCLs of 14 ppt and 18 ppt, respectively, apply to all PWSs, while the routine monitoring requirements apply to all CWS, NTNCWS and BVRB water systems in Pennsylvania. (Definitions of all these types of public water systems can be found in PADEP's Safe Drinking Water regulations at [25 Pa. Code § 109.1](#); the regulatory definitions of CWS, NTNCWS, and BVRB are also provided in the answer to FAQ #28 below.) The benefits associated with reductions of PFOA and PFOS in drinking water arise from a reduction in adverse human health effects. Exposure to PFOA is associated with adverse developmental effects (including neurobehavioral and skeletal effects) and exposure to PFOS is associated with adverse immune system impacts (including immune suppression). The rule also establishes the provisions necessary for PWSs to comply with the MCLs, including requirements for monitoring and reporting, public notification, consumer confidence reports, best available treatment technologies and

analytical requirements. By finalizing a Pennsylvania-specific PFAS MCL rule ahead of EPA’s PFAS National Primary Drinking Water Regulation, PADEP provided Pennsylvanians with several years earlier protection from the adverse health effects associated with exposure to these chemicals and also gave public water systems in Pennsylvania several years to begin earlier sampling for these chemicals and evaluating options to address elevated levels, where found.

Q21: How can I find out more information and contact PADEP about the Pennsylvania PFAS MCL rule?

A: To learn more about Pennsylvania’s PFAS MCL Rule, please visit PADEP’s [PFAS MCL Rule webpage](#). A summary of the drinking water PFAS MCL Rule is in PADEP’s Bureau of Safe Drinking Water’s [January 2023 Drinking Water News](#) newsletter.

If you have questions about Pennsylvania’s PFAS MCLs, interpreting sample results or information from your water system, contact PADEP’s Bureau of Safe Drinking Water at 717.787.9633 or RA-EPDWDTECHSUPPORT@pa.gov.

Q22: What would happen if PFAS chemicals stay in the water?


A: Decades of widespread use of products containing PFAS has resulted in elevated levels of environmental pollution and exposure in some areas of our planet, including some parts of Pennsylvania. PFAS remain in the environment and cycle through various media (air, water, soil) depending on how and where the substances were released. The primary means of distribution of PFAS throughout the environment has been through the air, water, biosolids, food, landfill leachate and firefighting activities. Because of their unique chemical structure, PFAS readily dissolve and are mobile in water, are highly persistent in the environment and bioaccumulate in living organisms over time.

Compliance Monitoring Results

Q23: What units are used to report compliance monitoring results and what do they mean?

A: All PFAS results are reported in nanograms per liter (ng/L) and/or parts per trillion (ppt), which are equivalent units, and equate to one-billionth of a gram of substance per liter of fluid (water).

1 ng/L or 1 ppt equates to 1 drop of water in 20 Olympic-sized swimming pools.



Q24: Where can I find PFAS compliance monitoring results for PWSs in Pennsylvania?

A: A summary of PFAS sample results submitted to PADEP by PWSs in Pennsylvania are posted on PADEP’s [PFAS MCL Rule webpage](#) on a quarterly basis.

Q24b: I clicked on the Pennsylvania PFAS Sampling Summary on PADEP’s [PFAS MCL Rule webpage](#); what does this table show and why is it important?

A: This table is a presentation of PWS monitoring results for compliance with Pennsylvania’s PFAS MCL Rule. Contained within the table are sampling results for Pennsylvania-regulated PFAS compounds – PFOA and PFOS – along with two additional PFAS compounds that currently do not have a Pennsylvania MCL but do have an EPA HAL – Hexafluoropropylene oxide dimer acid (HFPO-DA, also known as GenX) and Perfluorobutane sulfonic acid (PFBS).

Q25: Why are there additional PFAS compounds other than PFOA and PFOS reported?

A: Results for HFPO-DA and PFBS are from testing voluntarily conducted by PWSs. PWSs may elect to sample and report all PFAS compounds in addition to PFOS and PFOA.

Q26: Although there is no Pennsylvania MCL for HFPO-DA or PFBS, is there an EPA Health Advisory Level (HAL) for either contaminant?

A: Yes, the EPA HAL for HFPO-DA is 10 ppt, and the EPA HAL for PFBS is 2,000 ppt.

Q27: What is a Public Water System Identification Number (PWSID)?

A: A PWSID, or a Public Water System Identification Number, is a unique seven-digit identification number that identifies each regulated PWS within Pennsylvania.

Q28: What does PWS Type mean?

A: As defined in PADEP’s Safe Drinking Water regulations at [25 Pa. Code § 109.1](#), a PWS is a system which provides water to the public for human consumption which has at least 15 service connections or regularly serves an average of at least 25 individuals daily at least 60 days out of the year. As defined in § 109.1, there are various types of PWSs throughout Pennsylvania, including but not limited to:

- *Community water system (CWS)*—A public water system which serves at least 15 service connections used by year-round residents or regularly serves at least 25 year-round residents.
- *Nontransient noncommunity water system (NTNC)*—A noncommunity water system that regularly serves at least 25 of the same persons over 6 months per year
- *Bulk water hauling system*—A public water system which provides water piped into a carrier vehicle and withdrawn by a similar means into the user’s storage facility or vessel. The term includes, but is not limited to, the sources of water, treatment, storage or distribution facilities. The term does not include a public water system which provides only a source of water supply for a bulk water hauling system.
- *Bottled water system*—A public water system which provides water for bottling in sealed bottles or other sealed containers. The term includes, but is not limited to, the sources of water and treatment, storage, bottling, manufacturing and distribution facilities. The term does not include a public water system which provides only a source of water supply for a bottled water system and excludes an entity providing only transportation, distribution or sale of bottled water in sealed bottles or other sealed containers.
- *BVRB* – Refers to Bottled, Vended, Retail, and Bulk Water Hauling systems.

Q29: What does Entry Point (EP) Identification Number mean?

A: The Entry Point (EP) Identification Number is a number that identifies each EP within a PWS. An EP is a point acceptable to PADEP at which finished water representative of each source enters the distribution system.

Q30: What does a Non-Detect (ND) result indicate?

A: A Non-Detect (ND) result is a sample result value that is below the PADEP-accredited laboratory's reporting limit and cannot be accurately quantified.

FAQs for Water System Operators

Training

Q31: Is there any PFAS training for certified water operators available from PADEP?

A: PADEP held classroom training on Pennsylvania's PFAS MCL rule in the fall of 2023. The following is a 5-part virtual recording of the training course and the associated workbook: [PFAS Training Recording on YouTube \(Playlist\)](#) and [PFAS MCL Rule: DEP Operator Training Workbook](#).

Monitoring Requirements – General

Q32: Compliance monitoring began in 2024 for water systems serving more than 350 people and will begin in 2025 for systems serving 350 or fewer people, correct?

A: Under Pennsylvania's PFAS MCL Rule, initial quarterly monitoring for CWSs and NTNCWSs serving a population of more than 350 persons and BVRB systems began January 1, 2024, and initial quarterly monitoring for CWSs and NTNCWS serving 350 or fewer persons begins January 1, 2025.

This population breakdown was selected to evenly split initial monitoring across two years to ease laboratory capacity issues and allow small systems more time to prepare for compliance monitoring. Initial monitoring for all BVRB systems began January 1, 2024. Based on the number of PWSs and EPs in the Pennsylvania Drinking Water Information System (PADWIS) at the time Pennsylvania's PFAS MCL Rule was finalized, there are 1,885 EPs that began monitoring in year one (2024) and 1,900 that will conduct initial monitoring in year two (2025).

Q33: Will sample bottles be mailed to water systems each quarter for monitoring?

A: Each water system will need to make arrangements with a PADEP-accredited laboratory to conduct initial compliance monitoring required under the Pennsylvania's PFAS MCL Rule. The specifics of those arrangements -- including sample bottles, sample collection, delivery to the lab, etc. -- will need to be worked out between the individual water system and the lab.

Labs accredited for analysis of PFAS by one of the approved methods identified in the rule can be found at PADEP's [Laboratory Accreditation Program \(pa.gov\)](#); under the heading "Search Environmental Laboratories," select the [Search PA Accredited Environmental Laboratories Link](#).

Q34: Are PFOA and PFOS required in new source sampling for CWS and NTNC applications?

A: Yes.

Q35: Is the effective date for new source sampling Jan 14, 2023 or Jan 1, 2024?

A: The effective date for new source sampling requirements was January 14, 2023, which is the date the final regulation was published in the *Pennsylvania Bulletin* at [53 Pa.B. 533](#). A summary of the drinking water PFAS MCL Rule is in PADEP's Bureau of Safe Drinking Water's [January 2023 Drinking Water News](#) newsletter.

Q36: For any monitoring that would occur before initial monitoring is required, should the results be reported as Special samples?

A: No. Monitoring conducted at the entry point under § 109.302 is reported as sample type E. Monitoring conducted in accordance with permit conditions should be reported as specified in the permit. Additionally, monitoring under EPA's Fifth Unregulated Contaminant Monitoring Rule (UCMR 5) that is intended to count as initial compliance monitoring under Pennsylvania's PFAS MCL Rule is also reported as sample type E, *if the data meets all the requirements specified in Pennsylvania's PFAS MCL Rule.*

PADEP added § 109.301(16)(i)(C) to Pennsylvania's PFAS MCL Rule between the proposed and final stages in response to comments received to allow systems to change their initial monitoring schedule to align with UCMR 5 monitoring. This was done as a *potential* cost savings if systems are able to utilize the same set of data for both rules by meeting *all* requirements of both rules. *However*, PADEP did **not** include any language in Pennsylvania's PFAS MCL Rule that allows a PWS to change their initial monitoring schedule for any other reason, and PADEP did **not** include language to allow for grandparenting of data, including data collected in 2023. What that means is that if a PWS chooses to monitor prior to their scheduled start date in Pennsylvania's PFAS MCL Rule, that would be the PWS's choice for informational purposes, but it would **not** be in lieu of initial monitoring under that rule. The PWS would still need to conduct quarterly initial monitoring in either 2024 or 2025, depending on population (as described in the answer to FAQ #32 above).

That said, Pennsylvania's PFOA and PFOS MCLs are currently in effect, as is the one-hour reporting requirement. If a PWS chooses to conduct monitoring at the entry point prior to their initial compliance monitoring start date under Pennsylvania's PFAS MCL Rule, those results should be reported to PADEP's Drinking Water Electronic Laboratory Reporting (DWELR) System as sample type E samples. If the PWS has a detection that is over one or both Pennsylvania MCLs, the PWS is required to report that to PADEP within one hour of learning of the results.

Repeat monitoring would be dependent on the results during initial monitoring. If the PWS has four quarters of non-detects during initial quarterly monitoring, repeat monitoring is triennial (§ 109.301(16)(iii)); there is no waiver to apply for triennial monitoring.

Q37: If a PWS were to begin monitoring early and all results are non-detect (ND), would they then be able to use those results towards the requirements of the use waiver?

A: No. PWSs that have all ND results during initial monitoring have no need of a waiver because they will be automatically reduced to a triennial monitoring frequency. The *only* monitoring waivers included in Pennsylvania's PFAS MCL Rule are only applicable to systems that are on an annual monitoring schedule due to a previous detection (§ 109.301(16)(vii)).

Q38: If a small PWS with a population under 350 starts PFAS monitoring in 2024 rather than waiting until 2025, will the results count as initial monitoring under Pennsylvania's PFAS MCL Rule? In other words, can PADEP allow initial monitoring earlier than the schedule in the regulation?

A: The short answer is that PADEP *cannot* allow PWSs to conduct initial compliance monitoring outside of the schedule specifically stated in § 109.301(16)(i). Based on that language, there are three possible schedules for initial monitoring:

“(A) Systems serving more than 350 persons shall begin monitoring during the quarter beginning January 1, 2024.

(B) Systems serving 350 or fewer persons shall begin monitoring during the quarter beginning January 1, 2025.

(C) Upon request, a system required to conduct monitoring under the Fifth Unregulated Contaminant Monitoring Rule (UCMR 5), specified in 40 CFR Part 141, may upon written approval from the Department modify the initial monitoring period required under clause (A) or (B) to coincide with UCMR 5.”

This regulatory language does not support PADEP allowing an initial monitoring schedule other than listed above. That means that the only option for changing the schedule from the default start dates in § 109.301(16)(i)(A) and (B) based on population is to align the schedule with the UCMR 5 schedule, as stated in § 109.301(16)(i)(C).

If a PWS chooses to conduct voluntary monitoring prior to their scheduled start date in Pennsylvania’s PFAS MCL Rule, that would be the PWS’s choice for informational purposes, but it would **not** be in lieu of initial monitoring. The PWS would still need to conduct quarterly initial monitoring in either 2024 or 2025, depending on population (as described in the answer to FAQ #32 above).

Also, Pennsylvania’s PFOA and PFOS MCLs are currently in effect, as is the one-hour reporting requirement. If a PWS chooses to conduct monitoring at the entry point prior to their initial compliance monitoring start date, those results should be reported to DWELR as sample type E samples. If the PWS has a detection that is over one or both Pennsylvania MCLs, the PWS is required to report that to PADEP within one hour of learning of the results.

Q39: If a PWS is granted reduced monitoring but would like to continue monitoring quarterly, will PADWIS be able to track quarterly monitoring?

A: Monitoring and reporting frequencies will be determined according to requirements of Pennsylvania’s PFAS MCL Rule. Since PADEP cannot require quarterly monitoring if the rule does not support it, PADWIS will determine monitoring and reporting compliance and frequency changes as supported by the rule. It should be noted that if a PWS chooses to monitor more frequently than required, the Comprehensive Monitoring Plan should reflect this increased monitoring.

Monitoring requirements for consecutives and interconnections

Q40: Does a consecutive system, that solely purchases water from another PWS, need to test for PFAS under Pennsylvania’s PFAS MCL Rule?

A: Consecutive systems that obtain all of their water from another PWS may be exempt from monitoring for PFAS under § 109.301(16). The rulemaking modified § 109.301(8)(iii) to add PFAS monitoring under paragraph (16) to the list of contaminants that consecutives do not need to monitor for if the selling PWS conducts the required monitoring and is in compliance with the MCLs (see below).

“(8) Monitoring requirements for public water systems that obtain finished water from another public water system.

* * * * *

(iii) Consecutive water suppliers may be exempt from conducting monitoring for the MCLs for VOCs, SOCs, IOCs, radionuclides and PFAS if the public water system from which the finished water is obtained complies with paragraphs (5)—(7), (14) and (16) and is in compliance with the MCLs, except that asbestos monitoring is required in accordance with subparagraph (ii).”

Q41: Monitoring requirements “apply to all community water systems (CWS), nontransient noncommunity water systems (NTNCWS),” and at “...each entry point to the distribution system...”. Also “Paragraph (8)(iii) is amended to clarify that consecutive water systems may be exempt from PFAS monitoring, in addition to volatile synthetic organic chemicals (VOCs), SOCs, inorganic chemicals (IOCs) and radionuclides.” What about interconnections to CWSs or NTNCs that are not consecutive systems? Because interconnections are listed as entry points, is there any wording in Pennsylvania’s PFAS MCL Rule that allows for entry points receiving water from a PWS that has already monitored for PFAS to be exempt from monitoring? Or does the rule intend to have systems with interconnections monitor the water again at the interconnection entry point?

A: The intent of Pennsylvania’s PFAS MCL Rule is that compliance monitoring for PFOA and PFOS applies to EPs the same as EP monitoring for SOCs, VOCs, etc. If a PWS has one EP served by their own source or sources, and a second EP that is an interconnection to another PWS, EP monitoring is required at the first EP, but is not required at the interconnection as long as the selling PWS is conducting the required monitoring and results are at or below the MCLs. Monitoring would generally only be required at a purchased EP if there is reason to believe that it may be exceeding an MCL, under § 109.302.

There is existing language in § 109.301(8)(iv) that did not need to be amended with this rulemaking, which clarifies this exemption for interconnections at PWSs that do not meet the definition of a consecutive: “For a public water system which is not a consecutive water system, the exemption in subparagraph (iii) applies to entry points which obtain finished water from another public water system.”

Q42: Will a consecutive system have to begin their own monitoring if the system they purchase from would ever have an MCL exceedance or violation? If so, would that work similar to addition of a new source where the monitoring would have to begin in the next quarter? Would the sampling location be at the point of interconnection?

A: The monitoring exemption for consecutive systems and purchased EPs applies when the selling system is conducting the required monitoring *and* is in compliance with the MCLs.

If the selling system has an MCL exceedance, that exemption would no longer apply *unless* the interconnection is receiving water from a portion of the seller’s system that is physically or hydraulically separate from the seller’s source(s)/EP that has the exceedance. If the interconnection is (or is potentially) receiving water from the seller’s source(s)/EP that has the MCL exceedance, the purchasing system would be required to conduct monitoring at their EP (i.e. the interconnection) as soon as possible under § 109.302 in order to determine whether or not they are meeting Pennsylvania’s MCLs. Monitoring by the purchasing system may need to continue as long as the selling system exceeds one or both of Pennsylvania’s MCLs.

Q43: For an out-of-state PWS that sells water to a Pennsylvania water system, who is responsible for sampling?

A: If the out-of-state PWS is conducting monitoring for PFOA and PFOS, the purchasing PWS may be exempt from monitoring if the selling PWS meets the sampling and analytical criteria and monitoring frequency specified in Pennsylvania’s PFAS MCL Rule. If not, the purchasing (consecutive) PWS is (or should be) permitted by PADEP, so the purchasing PWS would be required to conduct monitoring at their EP(s). The purchasing PWS should contact the local DEP office to discuss their PFAS monitoring requirements.

Q44: For an out-of-state bulk water hauler that sells water to a Pennsylvania water system, who is responsible for sampling?

A: The out of state bulk water hauler needs to be permitted by PA DEP to sell water within PA, so they would be required to conduct monitoring the same as any other regulated bulk-hauling water system. If the bulk hauler is responding to an emergency situation, monitoring requirements should be specific in the emergency permit for both the bulk hauler and the purchasing water system

Q45: Do Pennsylvania's MCLs only apply to CWSs and NTNCWSs?

A: Pennsylvania's PFOA MCL of 14 ppt and PFOS MCL of 18 ppt apply to *all* PWSs, including CWSs, NTNCWSs, transient noncommunity water systems (TNCWSs) and BVRB water systems. TNCWSs are not required to conduct routine monitoring for PFAS under Pennsylvania's PFAS MCL Rule, but Pennsylvania's MCLs still apply to TNCWSs.

Q46: What are the requirements for TNCWSs?

A: TNCWSs are not required to conduct routine monitoring for PFAS under Pennsylvania's PFAS MCL Rule. However, as with all MCLs, Pennsylvania's PFOA and PFOS MCLs do still apply to TNCWSs. PADEP can require special monitoring under § 109.302 if PADEP have reason to believe a TNCWS is not complying with an MCL.

Sampling, labs, and analytical methods

Q47: What is PADEP's recommended sampling protocol? Are field and equipment blanks required for PFOA/PFOS considering the low (ng/L) detection/reporting levels?

A: Samplers should contact the laboratory that will be conducting the analysis for specific sampling instructions. The approved methods specify the quality assurance and quality control (QA/QC), including the need for blanks. Generally, a field reagent blank is required and would be analyzed if the sample has detections for PFOA and/or PFOS. Because PFAS are generally considered to be ubiquitous, the presence of PFAS in many consumer products is assumed. Preparation is essential in minimizing the likelihood of cross-contamination when collecting samples for PFAS analysis. Sample collectors should try to use clothing that is made of natural fibers (such as 100% cotton and denim), shoes that are (to the extent possible) constructed of natural material (such as untreated leather or canvas), or PVC or polyurethane, and personal care products that are 100% natural, and avoid handling or using products that may contain PFAS. Handwashing and wearing nitrile gloves can also help prevent cross contamination.

Tips for avoiding cross-contamination while collecting PFAS samples are available in PADEP's [PFAS Sampling Fact Sheet 3910-FM-BSDW0049](#).

Q48: Does PADEP's Laboratory Accreditation Program (LAP) have any type of oversight over sample collection techniques? Is that part of a lab's accreditation? What can be done to ensure proper collection techniques are followed?

A: For the EPA methods for PFAS, the sample collection is specified in the method. LAP's oversight regarding sample collection is that the procedure in the method be followed. The LAP generally does not assess sample collection technique or provide training. PADEP's lab accreditation regulations at 25 Pa. Code Chapter 252 require the lab to provide a sample collection standard operating procedure (SOP), which LAP reviews during an assessment.

LAP has more oversight over sample collectors that are employed by the lab as opposed to samples collected by the clients (like PWSs). Again, the lab is required to have a sample collection SOP and to follow the specific sampling requirements in the method.

Q49: What is the difference between field duplicates and field reagent blanks?

A: Field duplicates are essentially duplicate samples that the lab analyzes to demonstrate precision, or repeatability. Field reagent blanks are lab-grade reagent water that is exposed to sampling conditions to determine if any cross-contamination may be present. Field duplicates and field reagent blanks are required by and defined in the approved methods for PFAS analysis. The definitions in EPA Method 537.1 are as follows:

3.7. FIELD DUPLICATES (FD1 and FD2) – Two separate samples collected at the same time and place under identical circumstances, and treated exactly the same throughout field and laboratory procedures. Analyses of FD1 and FD2 give a measure of the precision associated with sample collection, preservation, and storage, as well as laboratory procedures.

3.8. FIELD REAGENT BLANK (FRB) – An aliquot of reagent water that is placed in a sample container in the laboratory and treated as a sample in all respects, including shipment to the sampling site, exposure to sampling site conditions, storage, preservation, and all analytical procedures. The purpose of the FRB is to determine if method analytes or other interferences are present in the field environment.

Q50: Are field duplicates required?

A: Field duplicates are a required QC element in the methods, but they are not required for every sampling event. Samplers should follow instructions provided by their laboratory for sample collection, including collection of any QC samples such as field duplicates. If the lab requests field duplicates and provides additional bottles, the sampler should collect the additional samples as requested.

Q51: Are field reagent blanks (FRBs) required?

A: Field reagent blanks (FRB) are also a method requirement. FRBs are required to accompany each sample set, which consists of samples collected from the same sample site at the same time. That means, to meet method requirements, each sample location needs to have a corresponding FRB collected and submitted to the lab. Because it is a method requirement, labs should not accept PFAS samples for analysis by one of the approved methods without an accompanying FRB. However, if the lab does accept and analyze a sample for which there was no FRB submitted, or if the FRB is lost in the lab for any reason, that is not a reason to invalidate the sample and those results would still be reportable. It should also be noted that the methods allow for the FRB to not be analyzed if the corresponding sample does not have detections. Some labs may offer cost savings if the FRB does not need to be analyzed.

Q52: Do FRB results get reported to DWELR?

A: No, FRB results do not get reported to DWELR.

Q53: If the FRB is not collected, or if it is collected but then subsequently “lost” at the lab prior to analysis, is that a reason to invalidate the sample?

A: No, a missing FRB is not a reason to invalidate a sample.

Q54: If the FRB is collected and analyzed and there is some sort of QC failure associated with it, can the sample results for the corresponding compliance sample be submitted?

A: In this case, the lab must submit a [Request to Report Qualified Drinking Water Sample Results Form](#) (1500-FM-BOL0010) *before* reporting the corresponding sample result to DWELR.

Q55: Will PADEP consider invalidating samples based on sampling conditions that the collector documents during sample collection? If not, why do we recommend that they document sampling conditions?

A: It is always good practice to document sampling conditions whenever collecting samples. If a sampler notes something during sample collection that they are concerned may cause false positive results, they should do their best to eliminate that potential source of cross-contamination prior to collecting a compliance sample. PADEP will likely not allow sample invalidation based on sampling conditions. However, referring back to notes from previous samples can help a sample collector in determining what to be aware of for future sample collection.

Compliance

Q56: What are the MCLs for PFOS and PFOA?

A: PADEP’s Bureau of Safe Drinking Water’s PFAS MCL Rule was published in the *Pennsylvania* Bulletin on January 14, 2023 at [53 Pa.B. 533](#) and set the PFOS MCL enforceable standard at 18 parts per trillion (ppt) and the PFOA MCL enforceable standard at 14 ppt. These MCLs became effective immediately upon publication of the rule on January 14, 2023, so any monitoring that results in an exceedance of an MCL will require the PWS to notify PADEP within one hour, per § 109.701(a)(3). The MCLs for PFOA and PFOS, in accordance with § 109.202(a)(4)(ii), are as follows:

Contaminant Name	MCL in ppt
Perfluorooctane sulfonate (PFOS)	18 ppt
Perfluorooctanoic acid (PFOA)	14 ppt

A summary of the drinking water PFAS MCL Rule is in PADEP’s Bureau of Safe Drinking Water’s [January 2023 Drinking Water News](#) newsletter.

Q57: Will compliance be determined quarterly or monthly? If compliance is determined quarterly, will that create a lag time for PWSs and PADEP to learn about MCL violations?

A: PADEP’s regulations specifically state that MCL compliance is determined quarterly, as is done for all chemical constituents (IOCs, VOCs, SOCs, Rads). There are several tools in place to ensure PADEP knows about exceedances as soon as possible, such as one-hour reporting, the 24-hour notice from the lab and the email notification from DWELR when results above an MCL are submitted. PADEP staff may manually review the data to determine whether a violation has occurred before the end of the quarter.

Q58: Does a PWS incur a violation if a PFOS and/or PFOA quarterly sample is missed? If so, is public notification required?

A: Yes and yes. If PFOS and/or PFOA is not monitored within the required quarter or reported by the deadline, the PWS incurs a monitoring/reporting violation in accordance with the provisions of 25 Pa. Code § 109.301 and § 109.701. The PWS is required to issue a Tier 3 Public Notice (PN) to customers within one year, in accordance with 25 Pa. Code Chapter 109, Subchapter D (relating to public notification). The Tier 3 PN can be included in the CCR.

Q59: What if the PFOS and/or PFOA sample result exceeds the respective MCL?

A: The PWS is required to notify PADEP within one-hour of receipt of any result that exceeds any MCL value to ensure timely consultation and oversight regarding investigative and corrective actions in accordance with the provisions of 25 Pa. Code § 109.7031(a)(3)(iii), (relating to reporting and recordkeeping).

Q60: Does the PWS have to issue PN for a PFOS and/or PFOA sample result that exceeds the respective MCL?

A: PN is not required for a sample result MCL exceedance, *unless* the exceedance also causes an MCL violation according to the compliance determination. The PWS does have to notify PADWP within one hour for any MCL exceedance as noted in FAQ #59. The PWS may choose to notify their customers of these sample results because PADEP will be posting PFAS quarterly results on PADEP's website.

Q61: What if there is an MCL Violation?

A: The PWS is required to notify PADEP within one-hour of receipt of any result that causes an MCL violation to ensure timely consultation and oversight regarding investigative and corrective actions in accordance with the provisions of 25 Pa. Code § 109.701(a)(3)(iii). Within 30 days of the PFOS and/or PFOA MCL violation, the PWSs must also issue a Tier 2 Public Notice (PN) to all customers notifying them of the violation(s). It is important to note that the compliance determination is based on a Running Annual Average (RAA) when the monitoring frequency is quarterly, but compliance is based on the average of the EP result and any required confirmation sample when the monitoring frequency is annual or triennial.

Q62: How is the Running Annual Average (RAA) calculated?

A: The RAA is the average of the results for the most recent four calendar quarters and is calculated when the monitoring frequency is quarterly. For the MCL compliance determination during initial monitoring, please refer to pages 4-1 to 4-6 of the [PFAS MCL Rule: DEP Operator Training Workbook](#).

Q63: Are PWSs required to take a confirmation sample after receiving a PFOS and/or PFOA sample result that exceeds the respective MCL?

A: If the monitoring frequency is quarterly, a confirmation sample is not required. In that case, it is up to the discretion of the PWS to take a confirmation sample. If the monitoring frequency is annual or less frequent, a confirmation sample must be collected within two weeks.

Q64: If a confirmation sample is collected on time, but after the 10th of the month after the EP sample, is the result of the confirmation sample used for MCL compliance? For example, a routine annual sample (sample type E) is collected on September 30 and exceeds an MCL and is reported by October 10th, but the confirmation sample (sample type C) is not collected until October 12, which is still within the required two weeks, but is not reported until November 10th. How is compliance with the MCL determined? Will the confirmation sample be used to average with the routine sample for compliance determination? Will the PWS incur a monitoring violation?

A: While PADEP's regulations allow up to two weeks to collect the confirmation sample, the end of the monitoring period/reporting deadline supersedes the two weeks allowed for the confirmation sample. Sample type E and C results must *both* be received by the 10th of the month following the end of the quarter. Using the example, if the C result is not reported by October 10, it is not counted in the compliance determination for the July-September quarter, so the PWS would incur a type 01 MCL violation and a type 04 check sample Monitoring/Reporting (M/R) violation. However, if the C result is reported in November, the E and C data would then be used to calculate a July-September quarterly average for the RAA calculation done at the end of the October-December quarter.

Q65: How are confirmation samples used for compliance if multiple C samples are reported within the two-week timeframe?

A: The PFAS compliance program will include all type 'C' samples if they are reported properly within the required time frame. All type 'E' and 'C' samples are averaged together to determine a quarterly value that is used for the compliance determination.

Q66: Will triennial monitoring be allowed at any time during the VOC/SOC year? Or will it be required during a specific quarter?

A: PWSs attain the triennial monitoring frequency for PFAS because there were no PFOA or PFOS detections during initial quarterly monitoring, so there are no results that would indicate a highest historic quarter. Therefore, triennial monitoring can be done any time during the appropriate calendar year in the three-year compliance period.

Q67: If a sample fails QC and the PWS recollects outside the required quarter, will they incur a M/R violation for that quarter, or can PADEP use discretion?

A: As is the case for all other chemical constituent monitoring, the PWS would incur a type 03 M/R violation that should be validated because a result was not reported for the required monitoring period. A PWSs should not wait until the end of the monitoring period to collect samples. PADEP does not have discretion when identifying violations; PADEP may use discretion regarding any enforcement actions.

Q68: For a system on annual monitoring, will it definitely be a monitoring violation if a system doesn't monitor in the historic highest quarter of previous detection, but still monitors in that year? (For example, if they are supposed to monitor in Q1, but don't monitor until Q2, is it still a violation even though they are still ultimately monitoring in that calendar year)? In other words, will DEP be tracking the quarter with the highest quarterly results?

A: Annual monitoring because of a previous detection must be done in the quarter with highest previous result. This information will be displayed with the Monitoring Information details in PADEP's Drinking Water Reporting System (DWRS), the public website.

Q69: Will the highest quarter be indicated in some way on monitoring calendars, or is it just going to be manual tracking to know which quarter is required?

A: Yes, as noted above, the highest quarter will be added to the DWRS Monitoring Calendars, but this will be for PFAS contaminants only.

UCMR 5

Q70: Systems sampling under UCMR5 may be able to use sample results for both UCMR 5 and PADEP PFAS MCL Rule initial monitoring. Have any labs had issues reporting for both UCMR 5 and PADEP?

A: PADEP has been informed by some labs that there may be issues with the QA/QC that are preventing labs from reporting the data for both purposes. There are three approved methods under Pennsylvania's PFAS MCL Rule (EPA Methods 537, 537.1, and 533) and PADEP can accept results analyzed by any of these methods, but UCMR 5 specifies that PFOA and PFOS must be analyzed by Method 533. The method specifies the required QA/QC, but there is an additional specification for QC under UCMR 5. Some labs may have been able to identify a way to analyze samples that meets both the general method requirement and the specific UCMR 5 requirement.

Q71: Is UCMR 5 data only reportable under Pennsylvania's PFAS MCL Rule if the lab is accredited by PADEP?

A: Yes. Data generated for UCMR 5 by a laboratory that is not PA-accredited would not be reportable to DWELR for compliance purposes.

Q72: What actions would PADEP require of PWSs related to UCMR 5 results originating from labs that are not PADEP accredited? Based on past experience, results will be posted in SDWARS through CDX within 90 days of collection, but there is no direct notification to the PWS.

A: In accordance with § 109.701(a)(3)(i), the PWS is required to notify PADEP within one hour of becoming aware of any results that exceed an MCL. Whether the lab reports the data to the water system, or the water system discovers the results by reviewing the data reported to SDWARS, one-hour reporting is required from the time the PWS learns of the results. Even if the lab is not PADEP-accredited, PADEP would not be able to ignore results exceeding an MCL. As confirmation of the result, PADEP would require the water system to have a sample analyzed by a PADEP-accredited lab, as per § 109.302. The results from the PADEP-accredited lab would be reportable to DWELR. Follow-up actions would be determined based on the results from the PADWP-accredited lab. For results that are detected at or below an MCL, no additional action is required.

Q73: With the limited control water systems would have over the EPA-contracted labs, to what extent is the data from those labs being looked at by PA DEP with regards to reporting requirements (DWELR)?

A: As noted above, in accordance with § 109.701(a)(3)(i), the PWS is required to notify PADEP within one hour of becoming aware of any results that exceed an MCL. Even if the lab is not PA accredited, we would not be able to ignore results exceeding an MCL. However, the data would not be reportable to DWELR.

Q74: For monitoring conducted under the UCMR 5 program, detections at or below Pennsylvania's MCLs do not get reported through DWELR, regardless of the lab's PADEP accreditation status, correct? So, as long as a PWS is not changing their PADEP-required start date for initial monitoring under Pennsylvania's PFAS MCL Rule and the UCMR 5 results are at or below Pennsylvania's PFOA and PFOS MCLs, reporting of the data through DWELR is not required. Is this correct?

A: Correct. UCMR 5 data is not required to be reported to DWELR, even if the lab is PADEP-accredited. If the PWS would like the UCMR 5 data analyzed by a PADEP-accredited lab to be reported to DWELR, the PWS needs to consult with the lab. Regardless, whether or not the lab is reporting the data to DWELR, the one-hour reporting requirement applies for any result exceeding an MCL.

Q75: How do we communicate UCMR 5 results to our customers?

A: UCMR results that are detected (over the UCMR reporting limits) must be reported in the CCR, according to 40 CFR 141.153.

Q76: We are large PWS (serving more than 10,000 people) that is required to monitor for PFAS under UCMR 5. Can these results also count towards initial compliance monitoring under Pennsylvania's PFAS MCL Rule?

A: It *may be* possible for the same set of data to count toward the monitoring requirements of both rules *if* the monitoring schedules align and *if all* requirements of both rules (UCMR 5 and Pennsylvania's PFAS MCL Rule) are met, including the monitoring period, frequency and number of samples collected, using an approved method and laboratory, and meeting all reporting requirements. It is the responsibility of the water system to ensure that all requirements are met and that the results are reported to DWELR.

If a PWS would like to align monitoring schedules for the two rules, the PWS can either modify their UCMR 5 schedule to coincide with initial compliance monitoring under Pennsylvania's PFAS MCL Rule, or the PWS can request to modify their initial compliance monitoring schedule under Pennsylvania's PFAS MCL Rule. PADEP included a provision to allow for that possibility in the final Pennsylvania PFAS MCL Rule.

Large water systems serving more than 10,000 people, should email UCMR_Sampling_Coordinator@epa.gov to request their UCMR 5 schedule be modified.

A PWS wishing to modify their initial compliance monitoring schedule under Pennsylvania's PFAS MCL Rule would need to complete and submit PADEP's *PFAS Initial Compliance Monitoring Schedule Change Request Form* (3930-FM-BSDW0051; linked below) **and** receive written approval from PADEP prior to modifying their compliance monitoring schedule.

- [PFAS INITIAL COMPLIANCE MONITORING SCHEDULE CHANGE REQUEST FORM AND INSTRUCTIONS.DOCX 3930-FM-BSDW0051](#)
- [PFAS INITIAL COMPLIANCE MONITORING SCHEDULE CHANGE REQUEST FORM AND INSTRUCTIONS.PDF 3930-FM-BSDW0051](#)

Again, aligning schedules is only the first step. It is important to remember that all requirements of both rules (UCMR 5 and Pennsylvania's PFAS MCL Rule) must be met for the data to be used for both purposes. PADEP has been informed by some labs that there may be issues with the QA/QC that are preventing labs from reporting the data for both purposes.

If a PWS chooses not to align the schedules, then the PWS would need to conduct monitoring for UCMR 5 according the schedule and requirements of that rule, *and* conduct monitoring for initial compliance with Pennsylvania's PFAS MCL Rule, quarterly beginning January 1, 2024, for systems serving more than 350 persons, in accordance with § 109.301(16)(i), and meeting all other requirements.

For more information, please visit PADEP's [PFAS MCL Rule webpage](#) to view the webinar for PFAS MCL Rule UCMR 5 monitoring overlap implications, under the "Training" heading.

Q77: Our PWS serves fewer than 10,000 people and started UCMR 5 sampling in 2023. Will the 2023 PFAS sampling cover us for the initial monitoring requirements of Pennsylvania's PFAS MCL Rule for 2024, or is additional sampling required under Pennsylvania's PFAS MCL Rule in 2024? How do we request that the 2023 UCMR 5 results count toward initial compliance monitoring under Pennsylvania's PFAS MCL Rule?

A: It *may* be possible for the same set of data to count for the monitoring requirements of both rules, *if* the monitoring schedules align and *if all* requirements of both rules are met, including reporting requirements. It is the responsibility of the water system to ensure that all requirements are met.

However, it is important to point out that for small and medium systems serving fewer than 10,000 people, there are a few challenges with this. Specifically, For UCMR 5 monitoring, EPA selects the laboratory for the water system from their list of UCMR 5 approved labs and pays for analysis. If that lab is not also PA-accredited for the specific method required under UCMR 5 (EPA Method 533 for PFOA and PFOS), PADEP will not be able to accept the monitoring data for compliance monitoring purposes under Pennsylvania's PFAS MCL Rule. Also, since EPA is paying for UCMR 5 analysis, EPA is the client of the laboratory, not the PWS; therefore, even if the lab is both UCMR 5-approved and PADEP-accredited, it will likely not be possible for the lab to report the data to PADEP in addition to reporting to SDWARS for UCMR 5.

Keeping that in mind, if you would like to align monitoring schedules for the two rules, you can either modify your UCMR 5 schedule to coincide with initial compliance monitoring under Pennsylvania's PFAS MCL Rule, or you can request to modify your initial compliance monitoring schedule under Pennsylvania's PFAS MCL

Rule. PADEP included a provision to allow for that possibility in the final Pennsylvania PFAS MCL Rule. To modify your UCMR 5 schedule, contact the EPA contractor for UCMR 5, Great Lakes Environmental Center (GLEC), at UCMR5@glec.com. To request to modify your initial compliance monitoring schedule under Pennsylvania's PFAS MCL Rule, you would need to complete and submit the *PFAS Initial Compliance Monitoring Schedule Change Request Form* (3930-FM-BSDW0051; linked below) and receive written approval from PADEP prior to modifying your compliance monitoring schedule. But, again, aligning schedules is only the first step; due to the challenges noted above, it still may not be possible to use the same set of data for both rules.

- [PFAS INITIAL COMPLIANCE MONITORING SCHEDULE CHANGE REQUEST FORM AND INSTRUCTIONS.DOCX 3930-FM-BSDW0051](#)
- [PFAS INITIAL COMPLIANCE MONITORING SCHEDULE CHANGE REQUEST FORM AND INSTRUCTIONS.PDF 3930-FM-BSDW0051](#)

Again, aligning schedules is only the first step. It is important to remember that all requirements of both rules must be met for the data to be used for both. We have been informed by some labs that there may be issues with the QA/QC that is preventing labs from reporting the data for both purposes.

If you chose not to align the schedules, then you would need to conduct monitoring for UCMR 5 according to the schedule and requirements of that rule, **and** conduct monitoring for initial compliance with Pennsylvania's PFAS MCL Rule, quarterly beginning January 1, 2024, for systems serving more than 350 persons, in accordance with § 109.301(16)(i), and meeting all other requirements.

For more information, please visit PADEP's [PFAS MCL Rule webpage](#) to view the webinar for PFAS MCL Rule UCMR 5 monitoring overlap implications, under the "Training" heading.

Q78: My PWS serves fewer than 10,000 people, designating us as a 'small' system under UCMR 5. One of my concerns was that EPA is going to select the accredited laboratory for small PWSs to complete the required UCMR 5 monitoring. Has PADEP inquired whether or not a small PWS may contact GLEC and request which accredited lab they will be assigned? If we may request to be assigned a PADEP-accredited laboratory, we can take advantage of at least two monitoring periods.

A: PADEP did ask EPA whether they would entertain requests by small systems that those systems' samples be sent to a lab that is both EPA-approved for UCMR 5 and PADEP-accredited. EPA's answer was that, yes, small systems can make that request, but EPA did not guarantee that they will be able to accommodate all such requests. Also, keep in mind that EPA will be paying for analysis and reporting to SDWARS for UCMR 5. If you are assigned a lab that is also PADEP-accredited, the lab must also be willing to report the results for Pennsylvania compliance via DWELR. All compliance data must be reported appropriately and on time via DWELR.

Cost Estimates

Q79: Do you know the additional testing cost?

A: Monitoring costs will depend on several different factors:

- which lab is doing the analysis
- whether the lab or the PWS collects the sample
- which method is used for analysis
- which parameters are being requested (PFOA, PFOS, both or the full range that the method can identify)

- how many samples are needed for each EP, and
- whether the field reagent blank also needs to be analyzed

The monitoring cost estimates are in Section G of the preamble to Pennsylvania’s PFAS MCL Rule, which begins on page 350 of [the Pennsylvania Bulletin issue](#) in which the rule was published; the compliance monitoring costs start on page 354. Immediately below is an excerpt of that information:

“Compliance monitoring costs

Compliance monitoring cost estimates for this final-form rulemaking were determined based on a survey conducted of laboratories accredited in this Commonwealth for PFAS analysis by one or more of the analytical methods in this final-form rulemaking, as well as assumptions made based on an analysis of the occurrence data. According to lab survey results, the analytical cost for PFAS by either EPA Method 533, EPA Method 537 version 1.1 or EPA Method 537.1 varied greatly among the labs that responded, with a range of \$325 to \$750, and an average of \$516, including the cost of analysis of the associated field reagent blank required by the methods for each sample site. This does not include an additional fee for sample collection, which also varied greatly among the labs offering that service; sample collection is approximately an additional \$200 based on the survey.

Approximately half of the responding laboratories noted that they offer a cost reduction for reporting of fewer analytes than included in the method, which would provide a cost savings for systems since monitoring is required for only two analytes—PFOA and PFOS. Also, a few labs noted potential savings if there are no detections in the sample; the associated field blank would be extracted, but would not need to be analyzed, which would reduce the overall cost. A few labs also noted potential additional fees for PFAS-free blank water, overnight shipping costs for samples and Level 4 data reports if requested.

For compliance monitoring cost estimates, it was assumed that approximately half of all water systems will collect their own samples and half will utilize sample collection services provided by the laboratory. Therefore, an average cost of \$616 per sample was used in the following compliance monitoring cost estimate calculations.”

If a PWS has an entry point (EP) with results over a Pennsylvania PFAS MCL, quarterly monitoring will be required to establish the contaminant levels over time. Compliance with the Pennsylvania MCLs is based on a running annual average of the quarterly results. Systems with MCL violations may resolve the issue by taking the affected source(s) offline, blending the affected source(s) with other sources to lower the levels detected at the EP or by installing treatment.

Q80: Do you know generally how expensive is it if a PWS exceeds Pennsylvania’s PFAS MCLs?

A: Treatment costs will also depend on several different factors, including:

- what contaminants are being treated
- the level of the contaminant being treated
- the level of other PFAS that may affect treatment efficacy
- the volume of water being treated

Treatment costs estimates are also included in Section G of the preamble and are based on treating an average of 1 million gallons per day (MGD). Sources that are rated for more than 1 MGD may have higher treatment costs; sources rated for less than 1 MGD may have lower costs.

Bottled, Vended, Retail, and Bulk (BVRB) Water Systems

Q81: Under Pennsylvania’s PFAS MCL Rule, PFAS analyses will be required for any assigned BVRB EPs starting in the first quarter of 2024, correct?

A: Correct

Q82: Under Pennsylvania’s PFAS MCL Rule, PFAS analyses will be required for any new BVRB sources or products for which approval is sought after January 14, 2023, and will be required of products for four consecutive quarters once approved, correct?

A: The first part is correct in that new source sampling conducted as part of the permitting process now needs to include analysis of PFAS. Any new products (EPs) permitted in 2023 will not begin initial quarterly monitoring until the first calendar quarter of 2024, *unless* new source sampling results indicate that monitoring is necessary sooner.

Q83: Is there any monitoring exemption for permit by rule (PBR) systems?

A: Vended systems that do *not* qualify for permit by rule are required to monitoring according to § 109.1003(a)(1).

However, vended systems that *do* qualify for permit by rule are required to monitor according to § 109.1003(a)(2):

“(2) Vended water systems shall monitor in accordance with paragraph (1) except that vended water systems qualifying for permit by rule under § 109.1005(b), for each entry point shall:

(i) Monitor monthly for microbiological contaminants.

(ii) Monitor annually for total dissolved solids, lead and cadmium.

(iii) Conduct special monitoring as required by the Department.

(iv) Beginning April 28, 2018, a system that obtains finished water from another permitted public water system using surface water or GUDI sources shall also monitor in accordance with paragraph (1)(xiv).”

Q84: What about a BVRB that has a source in another state?

A: Monitoring is required for PFAS if the selling system is not conducting monitoring at least annually, as noted above.

Treatment and Permitting

Q85: What is PADEP’s pilot study policy for installing PFAS treatment?

A: PADEP is requiring pilot studies on a case-by-case basis. If the technology has been demonstrated effective on similar raw water qualities, PADEP may decide to not require a pilot study. However, PADEP strongly encourages all systems to conduct a pilot study.

Q86: What is the frequency of sampling for PFAS during the pilot study? Where are the sampling locations? If there are filters in series, is there a sampling point in between the filters and post-filters?

A: PADEP does not yet have official guidance on pilot study sampling frequency and locations for PFAS treatment. PADEP is currently recommending weekly samples of the raw water, midpoint between pilot columns, and pilot effluent, to be analyzed for PFOA and PFOS.

Q87: If a PWS already has a permit allowing for multiple sources at one EP, with no blending rates specified, and they want to blend sources at a specific blending rate in order to meet the PFAS MCL, would that require a major or minor permit amendment?

A: This would be a minor amendment, as PADEP does not consider blending to be treatment and the special conditions for treatment would not be applicable for blending. PADEP would need to set different conditions to ensure the blended water is consistently under the MCL.

Q88: If a PWS installs ion exchange treatment for PFAS, would their monitoring frequency for lead and copper need to be reset to six-months initial monitoring? In other words, is ion exchange treatment likely to change the chemistry of the water leaving the treatment plant if they don't have some form of CCT?

A: Ion exchange treatment temporarily alters the water chemistry just after the resin is newly installed, but it doesn't permanently alter water chemistry. The resin has chloride ions that are initially replaced by other anions in the water that are at much higher concentrations than PFAS. Gradually those other anions are displaced by PFAS. When the resin is newly installed, it loses a lot of chloride ions initially as they are replaced by the other anions and the pH goes down as a result. The PWS would need to filter-to-waste until the pH stabilizes after new media is installed. PADEP has a special condition to monitor effluent pH in order to capture this effect. There is an alternative resin available from one vendor that is buffered (that is, the resin already had the chloride ions replaced with typical anions that are in source water) and this minimizes filter-to-waste time.

This potential pH change is a temporary effect that is addressed by the filter-to-waste requirement in the operations permit conditions, so it should not affect water chemistry in the distribution system. Therefore, there should not be a need to reset the Pb/Cu tap monitoring frequency to every six-months *unless* an issue was identified during the simultaneous compliance evaluation that was completed during the permitting process.

Q89: Are there any distribution system components that may contribute to elevated PFAS levels in the distribution system?

A: NSF 61 does include PFOA and PFOS, and it is unlikely that HDPE or PVC pipe would be a source for PFAS.

Consumer Confidence Reports (CCR)

Q90: Is there any CCR specific language to be used in 2022 CCRs for PFAS contaminants now that the MCLs have been established in Pennsylvania?

A: When reporting PFAS data for calendar year 2022 in the 2023 CCR (delivered by July 2023), PWSs should report that monitoring was done for PFAS that were not regulated in 2022 and the results were [fill in the blank with the specific results for your system]. PWSs could add a footnote that the Pennsylvania PFAS MCLs were finalized in January 2023, so moving forward there will be enforceable regulatory standards for PFOA and PFOS.

CCR language is defined in Pennsylvania's PFAS MCL Rule in § 109.416(3.1) for future CCR years.

Q91: Now that PADEP has published Pennsylvania's PFAS MCL Rule, should PWSs still include language about the EPA interim HALs in CCRs? Currently, I have PFAS language for both contained in the template.

A: PADEP's recommendation when reporting PFAS data for calendar year 2022 in the CCR delivered in 2023, is to not provide a comparative number. PADEP recommends reporting that monitoring was done for PFAS

that were not regulated in 2022 and the results were [fill in the blank with the specific results for your system]. PWSs could add a footnote that the Pennsylvania PFAS MCLs were finalized in January 2023, so moving forward there will be enforceable limits for PFOA and PFOS.

The 2016 EPA HAL was superseded by interim HALs that are not technically feasible, so the risk communication message is challenging. These interim HALs were recently replaced by the MCLs in EPA's PFAS National Primary Drinking Water Regulation that was published in the *Federal Register* on April 26, 2024.

INTERNAL DRAFT